Biotech

Medovex provided a 30-day post procedure update on one of the first cases using its DenerveX System.

Medovex (NASDAQ:MDVX) provided a 30-day post procedure update on one of the first cases using its DenerveX System.
As quoted in the press release:

The case was conducted on July 15, 2017 and results were assessed via visual analog scale (VAS) at 30 days post procedure. According to the VAS score, the patient reported a 70% reduction in pain.
Medovex President and COO Patrick Kullmann, stated, “We are clearly very pleased with this 30 day post case assessment for one of the first in human procedures conducted on July 15, 2017. The early results, particularly this case, are in alignment with the longer term 3 year findings as indicated in a research paper published by Dr. Scott Haufe, the inventor of the DenerveX Device, titled ‘Endoscopic Facet Debridement for the Treatment of Facet Arthritic Pain — a novel new technique’ published in the International Journal of Medical Science in 2010.”
Kullmann added, “We look forward to reporting additional results and securing testimonials as early patients reach post case milestones of 30, 60 and 90 days.”

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX20111.51+121.15
TSXV599.81+5.12
DOW33747.86+32.49
S&P 5003992.93+36.56
NASD11323.33+209.18
ASX7158.00+194.00

COMMODITIES

Commodities
Gold1770.78+0.54
Silver21.71+0.01
Copper3.94+0.18
Palladium2050.78+7.00
Platinum1035.03+4.04
Oil88.86+2.39
Heating Oil3.48-0.09
Natural Gas5.90-0.34

DOWNLOAD FREE REPORTS

×